检索结果-南通市图书馆

Cellular & Molecular Immunology 2022年第2期19卷 296-298页

作者： Bokyung Min Bitna Yang You-Sun kim Gyeong Min Park hyunah kim Hyojin kim Eun-Ji kim Yu Kyeong Hwang Eui-Cheol Shin Sungyoo Cho BioMedical Science and Engineering Interdisciplinary Program KAISTDaejeonKorea Cell Therapy Research Center GC LabCellYonginKorea Laboratory of Immunology and Infectious Diseases Graduate School of Medical Science and EngineeringKAISTDaejeonKorea

Natural killer(NK)cells play an important role in the antitumor immune response as the major cytotoxic lymphocytes in the innate immune *** cells without any genetic modifications have been used for both autologous and allogeneic ***,many reports have suggested that allogeneic NK cells can reduce the recurrence of disease and improve survival through a graft-versus-leukemia effect without GVHD[1,2].

关键词： killer expressing optimal

Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Frontiers of Medicine 2019年第6期13卷 713-722页

作者： Seo Yeon Baik hyunah kim So Jung Yang Tong Min kim Seung-Hwan Lee Jae Hyoung Cho Hyunyong Lee Hyeon Woo Yim Kun-Ho Yoon Hun-Sung kim Department of Medical Informatics College of MedicineThe Catholic University of KoreaSeoul 06591Republic of Korea College of Pharmacy Sookmyung Women’s UniversitySeoul 04310Republic of Korea Division of Endocrinology and Metabolism Department of Internal MedicineSeoul St.Mary’s HospitalCollege of MedicineThe Catholic University of KoreaSeoul 06591Republic of Korea Clinical Research Coordinating Center Catholic Medical CenterThe Catholic University of KoreaSeoul 06591Republic of Korea Department of Preventive Medicine College of MedicineThe Catholic University of KoreaSeoul 06591Republic of Korea

Few long-term follow-up studies have compared the changes in renal function according to the type of statin used in *** compared the long-term effects of statin intensity and type on the changes in the glomerular filtration rate(GFR).We extracted data of patients who took statin for the first *** analyzed whether or not different statins affect the changes in GFR at 3 months after baseline and 4 years *** included 3678 patients and analyzed the changes in *** GFR decreased by 3.2%±0.4%on average 4 years after the first statin prescription,indicating statistically significant deterioration(from 83.5±0.4 mL/min/1.73 m2 to 79.9±0.4 mL/min/1.73 m2,P<0.001).When comparing the GFR among different statins,significant differences were observed between atorvastatin and fluvastatin(−5.3%±0.7%vs.1.2%±2.2%,P<0.05)and between atorvastatin and simvastatin(−5.3%±0.7%vs.−0.7%±0.8%,P<0.05).In pitavastatin(odds ratio[OR]=0.64,95%confidence interval[CI]=0.46-0.87,P<0.005)and simvastatin(OR=0.69,95%CI=0.53-0.91,P<0.008),the GFR rate that decreased by<60 mL/min/1.73 m2 was significantly lower than that of *** long-term statin intake,GFR changed with the type of *** work is the first in Korea to compare each statin in terms of changes in the GFR after the statin prescription.

关键词： statin glomerular filtration rate HMG-CoA reductase inhibitor chronic kidney disease

Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients： a phase Ⅰ/Ⅱ trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cellular & Molecular Immunology 2015年第1期12卷 87-95页

作者： Soyoung Baek Yong-Man kim Sung-Bae kim Choung-Soo kim Seog-Woon Kwon YongMan kim HyunSoo kim hyunah Lee Office of Biomedical Professors Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea Department of Gynecology Asan Medical Center University of Ulsan College of Medicine Seoul Korea Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul Korean Department of Urology Asan Medical Center University of Ulsan College of Medicine Seoul Korean Department of Laboratory Medicine Asan Medical Center University of Ulsan College of Medicine Seoul Korea FCB-Pharmicell Co Ltd Seoul Korea

While ovarian cancer （OvCa） responds well to surgery and conventional chemotherapy, a high recurrence rate of advanced OvCa is observed. In this phase Ⅰ/Ⅱ study, 10 OvCa patients with minimal residual disease were treated with autologous dendritic cells （DCs） and IL-2 to evaluate the safety and feasibility of this therapeutic strategy and to characterize the antigen-specific immune alterations induced through this treatment. Approximately 4 months after initial debulking and chemotherapy, patients received two subcutaneous doses of autologous monocyte-derived DCs pulsed with autologous tumor lysate and keyhole limpet hemocyanin （KLH） at 4-week intervals. After each DC inoculation, low-dose （200 mlU） IL-2 was introduced for 14 consecutive days as an immune adjuvant. The vaccination was well tolerated. In three out of 10 patients, the inclusion status after the initial therapy showed the maintenance of complete remission （CR） after DC vaccination for 83, 80.9 and 38.2 months without disease relapse. One patient with stable disease （SD） experienced the complete disappearance of tumor after DC vaccination, and this status was maintained for 50.8 months until tumor recurrence. In two patients with partial response （PR） was not responding to DC vaccination and their disease recurred. In the three patients with disease free long-term survival, significant immune alterations were observed, including increased natural killer （NK） activity, IFN-γ-secreting T cells, immune-stimulatory cytokine secretion and reduced immune-suppressive factor secretion after DC vaccination. Thus, in patients with NED status and increased overall survival, DC vaccination induced tumor-related immunity, potentially associated with long-term clinical responses against OvCa.

关键词： dendritic cell vaccine immune response ovarian cancer phase Ⅰ/Ⅱ trial

Identification of novel HLA-A 0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cellular & Molecular Immunology 2012年第2期9卷 175-183页

作者： Hyun Ju Lee Cheol Yi Hong Chun-Ji Jin Mi-Hyun kim Youn-Kyung Lee Thanh-Nhan Nguyen-Pham hyunah Lee Byoung Chul Park Ik-Joo Chung Hyeoung-Joon kim Je-Jung Lee Research Center for Cancer Immunotherapy Chonnam National University Hwasun Hospital Hwasun Jeollanamdo Korea Department of Hematology-Oncology Chonnam National University Gwangju Korea VaxcelI-Bio Therapeutics Hwasun Jeollanamdo Korea Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea Korea Research Institute of Bioscience and Biotechnology （KRIBB） Daejeon Korea The Brain Korea 21 Project Center for Biomedical Human Resources at Chonnam National University Gwangiu Korea

Anterior gradient-2 （AGR2） promotes tumor growth, cell migration and cellular transformation and its enhanced expression is almost completely restricted to malignant tissues, thus making AGR2 an interesting target for the development of immunotherapeutic strategies. We investigated whether the AGR2 molecule comprises human leukocyte antigen （HLA）-A 0201-binding epitopes recognized by human cytotoxic T lymphocytes （CTLs）, which could be targeted in dendritic cell （DC）-based cancer immunotherapy against colorectal cancer （CRC）. We reviewed the sequence of AGR2 for peptides that could potentially bind to HLA-A 0201 with the aid of a computer-based program. Five candidate peptides with different binding scores were synthesized and tested. These peptides were then assessed for their immunogenicity to elicit specific immune responses mediated by CTLs in vitro by means of enzyme-linked immunospot assays and CTL assays. AGR2 was highly expressed in several CRC cell lines, including DK01, DLD1, KM 12C, HCT-8 and HT-29. DCs pulsed with AGR2-P2 （aa 11-19; LLVALSYTL） or AGR2-P4 （aa 127-135; RIMFVDPSL） generated potent CTLs that could lyse T2 cells pulsed with AGR2-P2 or AGR2-P4 and HLA-A0201＋ AGR2-positive CRC cell lines in a strong dose-dependent and HLA-A 0201-restricted manner. In conclusion, these novel epitopes derived from AGR2 protein may be attractive candidates for DC-based immunotherapy for CRC.

关键词： AGR2 colorectal cancer dendritic cell tumor-associated antigen